

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

**VOLUNTARY ANNOUNCEMENT
MIXED PROTAMINE HUMAN INSULIN INJECTION
APPROVED FOR LAUNCH**

This announcement is made by YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announce that Mixed Protamine Human Insulin Injection (30R) (the “**Product**”), independently researched and developed by the Company, has undergone the assessment and approval process and obtained approval for launch from the China National Medical Products Administration.

Name of the drug (Chinese)	精蛋白人胰島素混合注射液 (30R)
Name of the drug (English)	Mixed Protamine Human Insulin Injection (30R)
Form	Injection
Specification	3ml: 300 units (prefilled pen-type)
Registration category	Biological products for treatment
Handling number	CXSS2200010Guo
Drug approval number	Guoyaozhunzi (國藥准字) S20230051
Certificate number	2023S01450

The Product is a premixed insulin product for treatment of diabetes. It consists of 30% soluble human insulin and 70% protamine human insulin. The Product is suitable for the treatment of diabetes through subcutaneous injection, characterised by its low incidence of hypoglycemia and being safe for use, can effectively control postprandial blood glucose, fasting blood glucose and glycosylated hemoglobin (HbA1c) levels. According to the market data from IMS China, the sales volume of diabetes drugs in China in 2022 reached approximately US\$4.84 billion, amongst which approximately 39.5% of the total sales of diabetes drugs in the market was attributable to the sales of domestic human insulin and its analogue drugs for 2022, indicating a considerable market potential.

The Product is a biological drug of the Group approved for launch. The cumulative research and development expense we invested in it was approximately RMB130.1 million. Moreover, the Group has long been involved in the treatment of diabetes with a comprehensive product plan and a complete product line in place. The Product being successfully approved for launch will be beneficial for the expansion of the Group's business of treating endocrine and metabolic diseases and further enrich the Group's product portfolio.

This announcement is made by the Company on a voluntary basis to keep investors informed of the latest business development of the Group, and contains no advertisement or intention regarding the use of any drug, surgical device, therapy or oral product.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfu
Chairman

Hubei, the PRC

25 September 2023

As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Hao and Mr. LI Shuang as executive Directors; Mr. TANG Xinfu as non-executive Director; and Mr. TANG Jianxin, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive Directors.